However, the focus on BRCA-deficient breast cancer prevented the examination of the effects of PARP inhibitors on ER positive breast cancer cells and, as a result, may be reducing the full therapeutic potential of these drugs. This evidence concerns the gene PARP1 and breast carcinoma.